Cystic fibrosis (CF) is a chronic lethal multi-system condition; however, most of the morbidity
and mortality is dependent on the status of the respiratory system. Progressive respiratory …

… The aforementioned data regarding the impact of ivacaftor on inflammation and lipid
metabolism are not surprising after the findings previously reported by O’Connor and colleagues […

Acute lung injury (ALI) is a severe illness with excess mortality and no specific therapy.
Protective actions were recently uncovered for docosahexaenoic acid-derived mediators, …

Lung diseases like cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD)
are associated with chronic airway inflammation. The aim of our study was to compare a …

Background: The novel and highly effective CFTR modulator combination of elexacaftor-tezacaftor-ivacaftor
(ETI) has been shown to improve lung function and body weight in people …

Background Patients with cystic fibrosis (CF) have a relevant morbidity and mortality caused
by CF-related liver-disease. While transient elastography (TE) is an established …

Rationale Sputum biomarkers hold promise as a direct measure of inflammation within the
cystic fibrosis (CF) lung, but variability in study design and sampling methodology have …

Specific immunotherapy (SIT) is a well-established and clinically effective treatment for allergic
diseases. A pollen allergoid formulated with the T helper type 1 (Th1)-inducing adjuvant …

The chitinase-like protein YKL-40 was found to be increased in patients with severe asthma
and chronic obstructive pulmonary disease (COPD), two disease conditions featuring …

Background Cystic fibrosis (CF) is an autosomal recessive genetic disorder that affects multiple
organs, including the lungs, pancreas, liver and intestine. Mutations in the cystic fibrosis …